KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Debt: 2020-2024

Historic Total Debt for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $27.4 million.

  • Recursion Pharmaceuticals' Total Debt fell 27.53% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 27.53%. This contributed to the annual value of $27.4 million for FY2024, which is 2303.42% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Total Debt of $27.4 million as of FY2024, which was up 2,303.42% from $1.1 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Total Debt ranged from a high of $27.4 million in FY2024 and a low of $536,000 during FY2022.
  • Its 3-year average for Total Debt is $9.7 million, with a median of $1.1 million in 2023.
  • Its Total Debt has fluctuated over the past 5 years, first crashed by 94.45% in 2021, then skyrocketed by 2,303.42% in 2024.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Total Debt stood at $11.4 million in 2020, then slumped by 94.45% to $633,000 in 2021, then declined by 15.32% to $536,000 in 2022, then spiked by 113.06% to $1.1 million in 2023, then surged by 2,303.42% to $27.4 million in 2024.